Lenalidomide
Showing 26 - 50 of 1,173
Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)
Completed
- Primary Central Nervous System Lymphoma
- Rituximab
- +2 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022
Multiple Myeloma Trial in Boston, Columbus (drug, biological, other)
Terminated
- Multiple Myeloma
- lenalidomide
- +3 more
-
Boston, Massachusetts
- +1 more
Nov 14, 2022
Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)
Recruiting
- Multiple Myeloma
- Ixazomib plus low-dose lenalidomide
- Ixazomib
-
Hangzhou, Zhejiang, ChinaYang Xu
Feb 9, 2023
Dermatomyositis Trial in Nanchang (Lenalidomide)
Not yet recruiting
- Dermatomyositis
- Lenalidomide
-
Nanchang, Jiangxi, ChinaDepartment of Rheumatology and Clinical Immunology, Jiangxi Prov
Aug 3, 2022
Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker
Completed
- Alkylating Agent-Related Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Laboratory Biomarker Analysis
- Lenalidomide
-
Houston, TexasM D Anderson Cancer Center
Oct 18, 2022
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023
Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))
Not yet recruiting
- Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
- intensity-modulated radiotherapy (IMRT)
- (no location specified)
Jun 4, 2023
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- PF-07901801
- +2 more
-
San Juan, Puerto RicoAuxilio Mutuo Cancer Center
Jan 19, 2023
Multiple Myeloma Trial in Torino (Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide,
Active, not recruiting
- Multiple Myeloma
- Melphalan, Prednisone, Lenalidomide
- +2 more
-
Torino, TO, ItalyDivision Of Hematology, A.O.U. Città della Salute e della Scienz
Mar 24, 2022
Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS) Trial in Boston
Active, not recruiting
- Langerhans Cell Histiocytosis (LCH)
- +2 more
- Lenalidomide
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 26, 2022
Leukemia, Lymphoma Trial in Houston (Rituximab, Lenalidomide)
Active, not recruiting
- Leukemia
- Lymphoma
- Rituximab
- Lenalidomide
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 11, 2022
Multiple Myeloma Trial in United States (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
-
Duarte, California
- +9 more
Jan 11, 2023
DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)
Recruiting
- DLBCL
- Tafasitamab and Lenalidomide
-
Hangzhou, Zhejiang, ChinaThe First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022
Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)
Not yet recruiting
- Follicular Lymphoma
- lenalidomide
- +2 more
-
Shanghai, Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023
Multiple Myeloma Trial in Nantong (Colchicine, Lenalidomide)
Recruiting
- Multiple Myeloma
- Colchicine
- Lenalidomide
-
Nantong, Jiangsu, ChinaAffiliated Hospital of Nantong University
Mar 25, 2023
CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)
Recruiting
- CNS Lymphoma
- +2 more
- Tafasitamab
- Lenalidomide
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Multiple Myeloma Trial in Seoul (Lenalidomide maintenance)
Recruiting
- Multiple Myeloma
- Lenalidomide maintenance
-
Seoul, Korea, Republic ofSamsung Medical Center
Aug 10, 2022
Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)
Recruiting
- Diffuse Large-cell B-cell Lymphoma
- plamotamab
- +2 more
-
Seattle, WashingtonSwedish Cancer Center
May 2, 2022
Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)
Active, not recruiting
- Mantle Cell Lymphoma
- Venetoclax
- +2 more
-
Duarte, California
- +2 more
Oct 18, 2022
Waldenström's Macroglobulinemia Trial in Busan (Lenalidomide, Bortezomib, Rituximab, Dexamethasone)
Recruiting
- Waldenström's Macroglobulinemia
- Lenalidomide, Bortezomib, Rituximab, Dexamethasone
-
Busan, Sue-gu, Korea, Republic ofKosin University Gospel Hospital
Mar 31, 2022
Chidamide in Recurrent and Refractory Diffuse Large b
Enrolling by invitation
- Diffuse Large B-cell Lymphoma
- Chidamide
- +2 more
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
Jan 9, 2023
Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone Hydrochloride Liposome
- +2 more
-
Wuhan, Hubei, ChinaDepartment of Hematology Tongji Hospital, Tongji Medical College
Oct 7, 2022
Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)
Recruiting
- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Glofitamab, Poseltinib, Lenalidomide
-
Seoul, Korea, Republic ofSeoul National University Hospital
Nov 28, 2022